We'd Better Think Twice Before Eradicating All Smallpox Virus Stocks

The global eradication of smallpox as a threat to human health is one of the milestone achievements of modern medical science. It was accomplished through a unique international collaboration sponsored by the World Health Organization (WHO) and directed by virologist Donald A. Henderson, who now serves as deputy assistant secretary in the United States Department of Health and Human Services. The principal research centers supporting the eradication program were in Moscow and in Atlanta. W

Written byLev Sandakhchiev
| 7 min read

Register for free to listen to this article
Listen with Speechify
0:00
7:00
Share

The principal research centers supporting the eradication program were in Moscow and in Atlanta. While this collaboration was proceeding, the Cold War also nourished a high degree of mutual suspicion between the U.S. and the then-USSR about the possible abuse of such research for potential application in biological weaponry. While there are many technical reasons for giving smallpox very low priority as a weapon threat, there was great pressure to conclude an agreement to destroy all research stocks of the smallpox (variola) virus, as part of confidence-building between the superpowers.

Meanwhile, the world has experienced enormous changes. Russia is no longer a military threat, and it is clear that its civilian research establishment shares the same medical and scientific values as the rest of the world's scientific community. Any lingering questions about secret military work would not be resolved by the proposed destruction of research stocks in civilian hands. We ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies